用于治疗高胆固醇血症的Inclisiran
Joel C Marrs1, Sarah L Anderson2
1College of Pharmacy, Department of Clinical Pharmacy & Translational Science, The University of Tennessee Health Science Center, Nashville, TN, USA.
Drugs in context
|December 6, 2024
概括
英克利西兰是一种小干扰RNA (siRNA),通过减少PCSK9的产生,有效降低LDL胆固醇. 这种新型疗法为管理高脂血症提供了安全和一致的选择.
科学领域:
- 药理学 药理学 是一个学科.
- 心血管医学 心血管医学
- 在RNA治疗方面,RNA疗法.
背景情况:
- 超脂血症的特征是LDL胆固醇升高,是心血管疾病的主要危险因素.
- 蛋白转化酶亚素/素9 (PCSK9) 在调节LDL胆固醇水平方面起着至关重要的作用.
- 目前的治疗方法通常需要终身坚持,并且可能有局限性.
研究的目的:
- 评估inclisiran的疗效和安全性,这是一种基于siRNA的新疗法,用于降低LDL胆固醇.
- 评估inclisiran作为饮食和他类药物治疗的辅助剂在患有高脂血症的成年人中的作用.
主要方法:
- 英克利西兰利用小干扰RNA (siRNA) 技术来沉默PCSK9mRNA转化在肝细胞中.
- 这种机制导致PCSK9合成减少,LDL受体降解减少,LDL-C清除增加.
- 与安慰剂相比,临床试验评估了它的疗效和安全性.
主要成果:
- 英克利西兰证明了持续的LDL-C降低,范围为44-54%.
- 治疗被发现是安全的,与安慰剂相比,严重不良事件没有显著增加.
- 由FDA (2021) 和EMA (2020) 批准,inclisiran适用于原发性高脂血症和异性家族性高胆固醇血症.
结论:
- 在患有高脂血症的患者中,Inclisiran为降低LDL胆固醇提供了一种强效和安全的治疗选择.
- 其不常见的剂量方案 (最初,然后每6个月一次) 可能会改善治疗的坚持.
- 英克利西兰被认为是高风险心血管患者的有价值的非他类药物治疗选择.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
532
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
532
01:21Drugs for Treatment of Constipation-Predominant IBS
134
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
134
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
147
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119